BioCryst Pharmaceuticals
BCRX
123 hedge funds and large institutions have $942M invested in BioCryst Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 41 increasing their positions, 27 reducing their positions, and 13 closing their positions.
192% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 13
60% more capital invested
Capital invested by funds: $588M → $942M (+$354M)
52% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 27
26% more funds holding
Funds holding: 98 → 123 (+25)
9% less call options, than puts
Call options by funds: $9.82M | Put options by funds: $10.8M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$12.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$8.61M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$8.51M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$6.23M |
| 5 |
PA
Perceptive Advisors
New York
|
+$5.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$49.1M |
| 2 |
VM
VHCP Management
New York
|
-$15.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.7M |
| 4 |
Millennium Management
New York
|
-$5.84M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.35M |
BCRX Hedge Fund Activity: Q2 2015 in Review
123 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2015, worth a combined $942M — up 60% from $588M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new BCRX positions and 13 closed out — a net gain of 25 holders — while 41 added to existing stakes and 27 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $12.5M. The largest seller was RA Capital Management, cutting an estimated $49.1M.
- 123 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2015, up from 98 in Q1 2015.
- Funds reported $942M of BioCryst Pharmaceuticals stock for Q2 2015, up 60% quarter-over-quarter.
- 38 funds opened new BioCryst Pharmaceuticals positions in Q2 2015 and 13 closed out, a net change of +25 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2015 was Baker Bros. Advisors, an estimated $12.5M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2015 was RA Capital Management, an estimated $49.1M sold.
Based on aggregated 13F filings for Q2 2015.